-
1
-
-
33846285411
-
NT-proBNP in patients after acute coronary syndrome with ST segment elevation subjected to early posthospitalization cardiologic rehabilitation
-
Irzmanski R, Piechota M, Barylski M, Banach M, Kowalski J, Serwa-Stepien E, et al. NT-proBNP in patients after acute coronary syndrome with ST segment elevation subjected to early posthospitalization cardiologic rehabilitation. Arch Med Sci 2006; 2: 262-267.
-
(2006)
Arch Med Sci
, vol.2
, pp. 262-267
-
-
Irzmanski, R.1
Piechota, M.2
Barylski, M.3
Banach, M.4
Kowalski, J.5
Serwa-Stepien, E.6
-
3
-
-
0036445726
-
Increase of adenosine plasma levels after oral trimetazidine: A pharmacological preconditioning?
-
Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002; 45: 69-72.
-
(2002)
Pharmacol Res
, vol.45
, pp. 69-72
-
-
Blardi, P.1
de Lalla, A.2
Volpi, L.3
Auteri, A.4
Di Perri, T.5
-
4
-
-
34447523485
-
Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?
-
Lopez N, Varo N, Diez J, Fortuno MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007; 75: 536-45.
-
(2007)
Cardiovasc Res
, vol.75
, pp. 536-545
-
-
Lopez, N.1
Varo, N.2
Diez, J.3
Fortuno, M.A.4
-
6
-
-
33750606896
-
Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention
-
Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmanski R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006; 48: 143-7.
-
(2006)
J Cardiovasc Pharmacol
, vol.48
, pp. 143-147
-
-
Kowalski, J.1
Barylski, M.2
Banach, M.3
Grycewicz, J.4
Irzmanski, R.5
Pawlicki, L.6
-
7
-
-
0034678082
-
The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase
-
Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
-
(2000)
Circ Res
, vol.86
, pp. 580-588
-
-
Kantor, P.F.1
Lucien, A.2
Kozak, R.3
Lopaschuk, G.D.4
-
8
-
-
27644492930
-
Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury
-
Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39: 893-999.
-
(2005)
J Mol Cell Cardiol
, vol.39
, pp. 893-999
-
-
Argaud, L.1
Gomez, L.2
Gateau-Roesch, O.3
Couture-Lepetit, E.4
Loufouat, J.5
Robert, D.6
-
9
-
-
3242810591
-
-
Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al.; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet2004; 364: 347-54.
-
Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al.; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet2004; 364: 347-54.
-
-
-
-
10
-
-
38549097298
-
The role of trimetazidine in inhibiting cardiomyocyte apoptosis
-
Ruixing Y. The role of trimetazidine in inhibiting cardiomyocyte apoptosis. Arch Med Sci 2007; 3: S17-S24.
-
(2007)
Arch Med Sci
, vol.3
-
-
Ruixing, Y.1
-
11
-
-
12844280008
-
Comparative efficacy of ranolazine vs. atenolol for chronic angina pectoris
-
Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine vs. atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311-6.
-
(2005)
Am J Cardiol
, vol.95
, pp. 311-316
-
-
Rousseau, M.F.1
Pouleur, H.2
Cocco, G.3
Wolff, A.A.4
-
12
-
-
34247526904
-
MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial
-
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007; 297: 1775-83.
-
(2007)
JAMA
, vol.297
, pp. 1775-1783
-
-
Morrow, D.A.1
Scirica, B.M.2
Karwatowska-Prokopczuk, E.3
Murphy, S.A.4
Budaj, A.5
Varshavsky, S.6
-
13
-
-
35148850168
-
-
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLINTIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-52.
-
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLINTIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-52.
-
-
-
-
14
-
-
0348129532
-
Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial
-
Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al.; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291(3): 309-16.
-
(2004)
JAMA
, vol.291
, Issue.3
, pp. 309-316
-
-
Chaitman, B.R.1
Pepine, C.J.2
Parker, J.O.3
Skopal, J.4
Chumakova, G.5
Kuch, J.6
-
15
-
-
11144356285
-
MARISA Investigators.Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
-
Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. MARISA Investigators.Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43(8): 1375-82.
-
(2004)
J Am Coll Cardiol
, vol.43
, Issue.8
, pp. 1375-1382
-
-
Chaitman, B.R.1
Skettino, S.L.2
Parker, J.O.3
Hanley, P.4
Meluzin, J.5
Kuch, J.6
-
16
-
-
33746192571
-
ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial
-
Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48(3): 566-75.
-
(2006)
J Am Coll Cardiol
, vol.48
, Issue.3
, pp. 566-575
-
-
Stone, P.H.1
Gratsiansky, N.A.2
Blokhin, A.3
Huang, I.Z.4
Meng, L.5
-
17
-
-
33646432742
-
Ranolazine and late cardiac sodium current - a therapeutic target for angina, arrythmia and more
-
Makielski JC, Valdivia CR. Ranolazine and late cardiac sodium current - a therapeutic target for angina, arrythmia and more. Brit J Pharmacol 2006; 148: 4-6.
-
(2006)
Brit J Pharmacol
, vol.148
, pp. 4-6
-
-
Makielski, J.C.1
Valdivia, C.R.2
-
18
-
-
0038804137
-
Polymorphic hydroxylation of perhexiline in vitro
-
Sorensen LB, Sorensen RN, Miners JO, Somogyi AA, Grgurinovich N, Birkett DJ. Polymorphic hydroxylation of perhexiline in vitro. Brit J Clin Pharmacol 2003; 55: 635-8.
-
(2003)
Brit J Clin Pharmacol
, vol.55
, pp. 635-638
-
-
Sorensen, L.B.1
Sorensen, R.N.2
Miners, J.O.3
Somogyi, A.A.4
Grgurinovich, N.5
Birkett, D.J.6
-
21
-
-
39449133618
-
The current role of statins in acute coronary syndrome
-
Kumar A, Cannon CP. The current role of statins in acute coronary syndrome. Arch Med Sci 2007; 3: S115-S125.
-
(2007)
Arch Med Sci
, vol.3
-
-
Kumar, A.1
Cannon, C.P.2
-
22
-
-
51549100500
-
Carvedilol modifies antioxidant status of patients with stable angina
-
Kowalski J, Banach M, Barylski M, Irzmanski R, Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett 2008; 13(2): 230-239.
-
(2008)
Cell Mol Biol Lett
, vol.13
, Issue.2
, pp. 230-239
-
-
Kowalski, J.1
Banach, M.2
Barylski, M.3
Irzmanski, R.4
Pawlicki, L.5
-
23
-
-
33750994335
-
Grupo de trabajo de la sociedad europea de cardiologia sobre el manejo de la angina estable. Guidelines on the management of stable angina pectoris. Executive summary
-
Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Grupo de trabajo de la sociedad europea de cardiologia sobre el manejo de la angina estable. Guidelines on the management of stable angina pectoris. Executive summary. Rev Esp Cardiol 2006; 59: 919-70.
-
(2006)
Rev Esp Cardiol
, vol.59
, pp. 919-970
-
-
Fox, K.1
Garcia, M.A.2
Ardissino, D.3
Buszman, P.4
Camici, P.G.5
Crea, F.6
-
25
-
-
33745683654
-
Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: Executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology
-
Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381.
-
(2006)
Eur Heart J
, vol.27
, pp. 1341-1381
-
-
Fox, K.1
Garcia, M.A.2
Ardissino, D.3
Buszman, P.4
Camici, P.G.5
Crea, F.6
-
27
-
-
38549135618
-
The role of trimetazidine in the treatment of heart diseases
-
Banach M. ed, Poznan, Poland: Termedia Publishing House
-
Banach M, Okonski P, Rysz J, Drozdz J, Zaslonka J. The role of trimetazidine in the treatment of heart diseases. In Banach M. ed. The role of trimetazidine in the treatment of heart diseases. Poznan, Poland: Termedia Publishing House, 2006: 35-64.
-
(2006)
The role of trimetazidine in the treatment of heart diseases
, pp. 35-64
-
-
Banach, M.1
Okonski, P.2
Rysz, J.3
Drozdz, J.4
Zaslonka, J.5
-
28
-
-
0033036313
-
-
Szwed H, Sadowski Z, Pachocki R, Domza-Bochenska M, Szymczak K, Szydlowski Z, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther1999; 13: 217-22.
-
Szwed H, Sadowski Z, Pachocki R, Domza-Bochenska M, Szymczak K, Szydlowski Z, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther1999; 13: 217-22.
-
-
-
-
29
-
-
18244401979
-
Combination treatment in stable effort angina using trimetazidine and metoprolol: Results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand
-
Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22: 2267-74.
-
(2001)
Eur Heart J
, vol.22
, pp. 2267-2274
-
-
Szwed, H.1
Sadowski, Z.2
Elikowski, W.3
Koronkiewicz, A.4
Mamcarz, A.5
Orszulak, W.6
-
30
-
-
16244386878
-
A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study
-
Rodriguez Padial L, Maicas Bellido C, Velazquez Martin M, Gil Polo B. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study. Rev Clin Esp 2005; 58: 57-62.
-
(2005)
Rev Clin Esp
, vol.58
, pp. 57-62
-
-
Rodriguez Padial, L.1
Maicas Bellido, C.2
Velazquez Martin, M.3
Gil Polo, B.4
-
31
-
-
18544408022
-
Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction
-
Güler N, Eryonucu B, Günes A, Güntekin U, Tuncer M, Ozbek H. Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 2003; 17: 371-4.
-
(2003)
Cardiovasc Drugs Ther
, vol.17
, pp. 371-374
-
-
Güler, N.1
Eryonucu, B.2
Günes, A.3
Güntekin, U.4
Tuncer, M.5
Ozbek, H.6
-
32
-
-
0032564373
-
Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group
-
Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalán R, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998; 98: 2227-34.
-
(1998)
Circulation
, vol.98
, pp. 2227-2234
-
-
Diaz, R.1
Paolasso, E.A.2
Piegas, L.S.3
Tajer, C.D.4
Moreno, M.G.5
Corvalán, R.6
-
33
-
-
0033817242
-
Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project - Free Radicals
-
Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project - Free Radicals. Eur Heart J 2000; 21: 1537-46.
-
(2000)
Eur Heart J
, vol.21
, pp. 1537-1546
-
-
-
34
-
-
26944485823
-
-
Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning, a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 2005; 112: 2085-88.
-
Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning, a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 2005; 112: 2085-88.
-
-
-
-
35
-
-
33750945444
-
L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury
-
Okonski P, Banach M, Rysz J, Barylski M, Irzmanski R, Piechota M, et al. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Ann Transplant 2006; 11: 26-32.
-
(2006)
Ann Transplant
, vol.11
, pp. 26-32
-
-
Okonski, P.1
Banach, M.2
Rysz, J.3
Barylski, M.4
Irzmanski, R.5
Piechota, M.6
-
36
-
-
38549169693
-
The role of trimetazidine in patients subjected to surgical revascularization
-
Banach M, Goch A, Rysz J, Ugurlucan M, Mikhailidis DP, Goch JH. The role of trimetazidine in patients subjected to surgical revascularization. Arch Med Sci 2007: 3: S52-S56.
-
(2007)
Arch Med Sci
, vol.3
-
-
Banach, M.1
Goch, A.2
Rysz, J.3
Ugurlucan, M.4
Mikhailidis, D.P.5
Goch, J.H.6
-
37
-
-
33747365277
-
Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina
-
Danchin N. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina. Am J Cardiol 2006; 98: 8J-13J.
-
(2006)
Am J Cardiol
, vol.98
-
-
Danchin, N.1
-
38
-
-
33744995586
-
Effects of metabolic triad (25% polarizing solution, mildronat, preductal MR) in acute myocardial infarction
-
131
-
Svanidze TD, Gorgoshidze ML, Tsintsadze IN, Glonti TG. Effects of metabolic triad (25% polarizing solution, mildronat, preductal MR) in acute myocardial infarction. Georgian Med News 2006; 131: 49-52.
-
(2006)
Georgian Med News
, pp. 49-52
-
-
Svanidze, T.D.1
Gorgoshidze, M.L.2
Tsintsadze, I.N.3
Glonti, T.G.4
-
39
-
-
46749156747
-
Clinical study of trimetazidine for myocardial protection in acute myocardial infarction
-
Dong XD, Hu DY, Jia SQ, Wang L, Yan SB.Clinical study of trimetazidine for myocardial protection in acute myocardial infarction. Zhonghua Nei Ke Za Zhi 2007; 46: 633-6.
-
(2007)
Zhonghua Nei Ke Za Zhi
, vol.46
, pp. 633-636
-
-
Dong, X.D.1
Hu, D.Y.2
Jia, S.Q.3
Wang, L.4
Yan, S.B.5
-
40
-
-
0035134803
-
A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction
-
for the LIST Study Group
-
Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, et al. for the LIST Study Group. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001; 77: 263-273
-
(2001)
Int J Cardiol
, vol.77
, pp. 263-273
-
-
Steg, P.G.1
Grollier, G.2
Gallay, P.3
Morice, M.4
Karrillon, G.J.5
Benamer, H.6
-
41
-
-
0036449297
-
Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty
-
Polonski L., Dec I. Wojnar R, Wilczek K. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin 2002; 18: 389-394.
-
(2002)
Curr Med Res Opin
, vol.18
, pp. 389-394
-
-
Polonski, L.1
Dec, I.2
Wojnar, R.3
Wilczek, K.4
-
42
-
-
0030957232
-
Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty
-
Birand A, Kudaiberdieva GZ, Batyraliev TA, Akgul F, Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997; 48: 413-22.
-
(1997)
Angiology
, vol.48
, pp. 413-422
-
-
Birand, A.1
Kudaiberdieva, G.Z.2
Batyraliev, T.A.3
Akgul, F.4
Usal, A.5
-
43
-
-
0026699975
-
Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine
-
Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992; 13: 1109-15.
-
(1992)
Eur Heart J
, vol.13
, pp. 1109-1115
-
-
Kober, G.1
Buck, T.2
Sievert, H.3
Vallbracht, C.4
-
44
-
-
5444220243
-
Efficacy of trimetazidine in patients with recurrent angina: A subgroup analysis of the TRIMPOL II study
-
Ruzyllo W, Szwed H, Sadowski Z, Elikowski W, Grzelak-Szafranska H, Orszulak W, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004; 20: 1447-54.
-
(2004)
Curr Med Res Opin
, vol.20
, pp. 1447-1454
-
-
Ruzyllo, W.1
Szwed, H.2
Sadowski, Z.3
Elikowski, W.4
Grzelak-Szafranska, H.5
Orszulak, W.6
-
45
-
-
33644542154
-
Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine
-
Kuralay F, Altekin E, Yazlar AS, Onvural B, Goldeli O. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine. Tohoku J Exp Med 2006; 208: 203-12.
-
(2006)
Tohoku J Exp Med
, vol.208
, pp. 203-212
-
-
Kuralay, F.1
Altekin, E.2
Yazlar, A.S.3
Onvural, B.4
Goldeli, O.5
-
46
-
-
34249283806
-
Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention
-
Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93: 703-7.
-
(2007)
Heart
, vol.93
, pp. 703-707
-
-
Bonello, L.1
Sbragia, P.2
Amabile, N.3
Com, O.4
Pierre, S.V.5
Levy, S.6
-
47
-
-
39449108558
-
-
von Haehling S, Anker S. Statins for heart failure: where to go from here? Arch Med Sci 2007; 3: S133-S141.
-
von Haehling S, Anker S. Statins for heart failure: where to go from here? Arch Med Sci 2007; 3: S133-S141.
-
-
-
-
48
-
-
0024637404
-
Value of trimetazidine in the long-term treatment of cardiomyopathies of ischemic origin
-
Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Value of trimetazidine in the long-term treatment of cardiomyopathies of ischemic origin. Ann Cardiol Angeiol (Paris) 1989; 38: 179-82.
-
(1989)
Ann Cardiol Angeiol (Paris)
, vol.38
, pp. 179-182
-
-
Brottier, L.1
Barat, J.L.2
Combe, C.3
Boussens, B.4
Bonnet, J.5
Bricaud, H.6
-
49
-
-
0034503715
-
Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy
-
Belardinelli R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000; 19: V35-9.
-
(2000)
Rev Port Cardiol
, vol.19
-
-
Belardinelli, R.1
-
50
-
-
0032189888
-
Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease
-
Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol. 1998; 82: 898-901.
-
(1998)
Am J Cardiol
, vol.82
, pp. 898-901
-
-
Lu, C.1
Dabrowski, P.2
Fragasso, G.3
Chierchia, S.L.4
-
51
-
-
1542496389
-
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy
-
Fragasso G, Piatti Md PM, HMonti LH, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146(5): E18-E25.
-
(2003)
Am Heart J
, vol.146
, Issue.5
-
-
Fragasso, G.1
Piatti, M.P.2
HMonti, L.H.3
Palloshi, A.4
Setola, E.5
Puccetti, P.6
-
52
-
-
0035208524
-
Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy
-
Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001; 22: 2164-2170.
-
(2001)
Eur Heart J
, vol.22
, pp. 2164-2170
-
-
Belardinelli, R.1
Purcaro, A.2
-
53
-
-
22244463240
-
Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: A 24-month study
-
El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005; 5: 271-8.
-
(2005)
Am J Cardiovasc Drugs
, vol.5
, pp. 271-278
-
-
El-Kady, T.1
El-Sabban, K.2
Gabaly, M.3
Sabry, A.4
Abdel-Hady, S.5
-
54
-
-
34249001974
-
Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention
-
Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007; 7(2): 143-50.
-
(2007)
Am J Cardiovasc Drugs
, vol.7
, Issue.2
, pp. 143-150
-
-
Labrou, A.1
Giannoglou, G.2
Zioutas, D.3
Fragakis, N.4
Katsaris, G.5
Louridas, G.6
-
55
-
-
12744261465
-
Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy
-
Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
-
(2005)
Heart
, vol.91
, pp. 161-165
-
-
Di Napoli, P.1
Taccardi, A.A.2
Barsotti, A.3
-
56
-
-
38549142043
-
The role of trimetazidine in heart failure
-
Fragasso G, Cuko A, Salerno A, Baratto F, Gardini C, Margonato A. The role of trimetazidine in heart failure. Arch Med Sci 2007; 3: S45-S51.
-
(2007)
Arch Med Sci
, vol.3
-
-
Fragasso, G.1
Cuko, A.2
Salerno, A.3
Baratto, F.4
Gardini, C.5
Margonato, A.6
-
57
-
-
38549115290
-
Refractory angina - current therapeutic challenge
-
Szwed H, Dabrowski R. Refractory angina - current therapeutic challenge. Arch Med Sci 2007; 3: S38-S44.
-
(2007)
Arch Med Sci
, vol.3
-
-
Szwed, H.1
Dabrowski, R.2
-
58
-
-
33747887613
-
A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure
-
Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 992-998
-
-
Fragasso, G.1
Palloshi, A.2
Puccetti, P.3
Silipigni, C.4
Rossodivita, A.5
Pala, M.6
-
59
-
-
34547777411
-
-
Nowak MS, Wybór K, Gos R, Zeman-Miecznik A, Waszczykowska A, Pastuszkaet M al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia. Arch Med Sci 2007; 3: 152-156.
-
Nowak MS, Wybór K, Gos R, Zeman-Miecznik A, Waszczykowska A, Pastuszkaet M al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia. Arch Med Sci 2007; 3: 152-156.
-
-
-
-
60
-
-
17844401000
-
The role of inflammation in the pathogenesis of atherosclerosis
-
Banach M, Markuszewski L, Zaslonka J, Grzegorczyk J, Okonski P, Jegier B. The role of inflammation in the pathogenesis of atherosclerosis. Przegl Epidemiol 2004; 58: 663-70.
-
(2004)
Przegl Epidemiol
, vol.58
, pp. 663-670
-
-
Banach, M.1
Markuszewski, L.2
Zaslonka, J.3
Grzegorczyk, J.4
Okonski, P.5
Jegier, B.6
-
61
-
-
34547794180
-
Weight reduction decreases NT-proBNP levels in obsese coronary patients with chronic diastolic heart failure
-
Cocco G, Chu D. Weight reduction decreases NT-proBNP levels in obsese coronary patients with chronic diastolic heart failure. Arch Med Sci 2007; 3: 112-116.
-
(2007)
Arch Med Sci
, vol.3
, pp. 112-116
-
-
Cocco, G.1
Chu, D.2
-
62
-
-
44149098471
-
Statins in the prevention of postoperative atrial fibrillation: Is there really no effect?
-
Banach M, Goch JH, Ugurlucan M, Mariscalco G, Rysz J. Statins in the prevention of postoperative atrial fibrillation: is there really no effect? Am Heart J 2008; 155(6): e53
-
(2008)
Am Heart J
, vol.155
, Issue.6
-
-
Banach, M.1
Goch, J.H.2
Ugurlucan, M.3
Mariscalco, G.4
Rysz, J.5
|